title: Engraftment for CD34 selected stem cell products is not compromised by cryopreservation.
abstract: BACKGROUND
  The coinfusion of haploidentical CD34+ selected peripheral blood stem cell products with umbilical cord blood (UCB) provides early neutrophil recovery, long-term UCB engraftment, and a lower incidence of graft-versus-host disease; however, this complex transplant presents a scheduling challenge for both the cellular therapy laboratory and the clinical team. Cryopreservation of the haploidentical product can facilitate scheduling, but has been previously shown to be associated with infusion reactions and delayed platelet (PLT) engraftment in allogeneic hematopoietic progenitor cell transplant.
  
  
  METHODS
  To test whether cryopreservation of the CD34+ selected product compromises the graft, we compared neutrophil and PLT engraftment kinetics for patients receiving freshly infused or cryopreserved products. Seventy-two products collected from haploidentical related donors were CD34+ selected and infused in a combined transplant with UCB: 32 were cryopreserved before infusion and 40 were infused fresh.
  
  
  RESULTS
  No adverse infusion events were reported in either group and there was no difference in neutrophil and PLT engraftment time between fresh and cryopreserved products.
  
  
  CONCLUSIONS
  Cryopreservation of a CD34+-selected product can be safely used in a combined transplant with UCB and does not affect engraftment time.
authors.affiliation: Department of Transfusion Medicine and Cellular Therapy, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
authors.forename: Ronit
authors.initials: R
authors.lastname: Reich-Slotky
authors.affiliation: Department of Transfusion Medicine and Cellular Therapy, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.|National Cord Blood Program, New York Blood Center, New York, New York.
authors.forename: Lohith S
authors.initials: LS
authors.lastname: Bachegowda
authors.affiliation: Department of Transfusion Medicine and Cellular Therapy, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
authors.forename: Michael
authors.initials: M
authors.lastname: Ancharski
authors.affiliation: Department of Medicine, Weill Cornell Medical College, New York, New York.
authors.forename: Usama
authors.initials: U
authors.lastname: Gergis
authors.affiliation: Department of Medicine, Weill Cornell Medical College, New York, New York.
authors.forename: Koen
authors.initials: K
authors.lastname: van Besien
authors.affiliation: Department of Transfusion Medicine and Cellular Therapy, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.|Department of Pathology, Weill Cornell Medical College, New York, New York.
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Cushing
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism*; D001781:Blood Component Removal / Q000379:methods; D016913:Blood Component Transfusion / Q000592:standards*; D001793:Blood Preservation / Q000009:adverse effects / Q000379:methods / Q000592:standards; D002469:Cell Separation / Q000379:methods; D015925:Cryopreservation / Q000379:methods; D005260:Female; D005312:Fetal Blood / Q000166:cytology* / Q000378:metabolism / Q000637:transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014184:Transplantation, Homologous / Q000592:standards
chemical_list: D018952:Antigens, CD34